SCHEMBL9290708

SCHEMBL9290708

Cc1nc(C(C)N)nc2c1CC(C)(C)CC2

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.33
ACHE P22303 6/20 0.33
PARP1 P09874 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
KDM4E B2RXH2 1/20 0.31
EEF2K O00418 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9287302 0.77 KDM4E (0.55) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL16479770 0.76 PDK1 (0.39) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL9284199 0.73 PDK1 (0.34) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL8880918 0.71 PDK1 (0.35) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL15434699 0.70 PDK1 (0.34) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL856644 0.68 PDK1 (0.33) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL15434696 0.68 PDK1 (0.33) PDK1PARP1TNKS2PARP2
SCHEMBL19886568 0.66 PARP1 (0.33) PDK1ACHEPARP1TNKS2PARP2
SCHEMBL7823693 0.65 LIMK1 (0.38) PDK1PARP1TNKS2PARP2
SCHEMBL856920 0.64 ADORA2A (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140073628-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE RICE KENNETH D (US) 2014-03-13 US disclosed
US-20140018347-A1 BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2014-01-16 US disclosed
WO-2012071501-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018347-A1 BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE MTOR, RICTOR, RPTOR PDK1 134/4885ACHE 4069/4885PARP1 3225/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDK1 90/4885ACHE 3487/4885PARP1 2511/4885
US-20140073628-A1 BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE MTOR, RPTOR, RICTOR PDK1 161/4885ACHE 4635/4885PARP1 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.